A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma

Samankaltaisia teoksia

• Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
  Tekijä: A. Ciernik, et al.
  Julkaistu: (2024-01-01)
• Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
  Tekijä: Alexander N Shoushtari, et al.
  Julkaistu: (2021-10-01)
• Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
  Tekijä: Vidhya Karivedu, et al.
  Julkaistu: (2019-01-01)
• Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
  Tekijä: Vidhya Karivedu, et al.
  Julkaistu: (2019-01-01)
• Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
  Julkaistu: (2020-10-01)